Health Canada approves Eli Lilly Foundayo pill for weight loss
Health Canada approved a new daily oral medication from Eli Lilly called Foundayo for treating obesity and Type 2 diabetes in adults on November 13.

New daily pill arrives in January
The medication is expected to become available in Canadian pharmacies starting in January. This new treatment offers an alternative to weekly injections like Ozempic or Wegovy for patients seeking weight management. Foundayo contains the active ingredient orforglipron which acts as a GLP-1 receptor agonist. The drug helps regulate appetite and blood sugar levels in eligible adults with obesity.
Eligible patients include those with high blood pressure
Approval covers overweight adults who have related health conditions such as sleep apnoea or high blood pressure alongside their weight issues. Vancouver endocrinologist Dr Ehud Ur told Global News that the pill could provide comparable weight loss benefits to existing treatments. He stated it seems just as good if not better than semaglutide and tirzepatide for losing weight. Yet, additional data from clinical trials must be gathered to determine if the drug provides comparable heart health advantages.
Common side effects include digestive problems
Common side effects of GLP-1 medications generally include nausea, vomiting and other digestive problems for users taking the drug. Another weight-loss pill from Novo Nordisk known as oral Wegovy is currently awaiting Health Canada approval separately. The new daily option allows patients to take medication once a day instead of using injectable treatments.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.